Viridian Therapeutics Q1 2024 Earnings Report
Key Takeaways
Viridian Therapeutics reported a net loss of $48.5 million for the first quarter ended March 31, 2024. The company's cash, cash equivalents, and short-term investments were $613.2 million as of March 31, 2024, which is expected to fund operations into the second half of 2026.
THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topline readout expected in September 2024.
THRIVE-2 VRDN-001 global phase 3 clinical trial for patients with chronic TED remains on track for topline readout by year-end 2024.
Positive VRDN-003 Type C meeting held with the US Food and Drug Administration (FDA); pivotal program on track to start mid-year 2024.
VRDN-006 FcRn inhibitor remains on track for Investigational New Drug (IND) submission by year-end 2024; non-human primate data expected for VRDN-008, a half-life extended FcRn inhibitor, in the second half of 2024.
Viridian Therapeutics
Viridian Therapeutics
Viridian Therapeutics Revenue by Segment
Forward Guidance
Viridian believes that its current cash, cash equivalents, and short-term investments will be sufficient to fund its operations into the second half of 2026.